Showing 1 - 9 of 9 Lung Cancers
A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Determine early biomarkers involved in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

NRG-LU005

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Tanya Khan

Phone: 346.238.5655

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

REFINING LOW DOSE CT LUNG CANCER SCREENING USING BLOOD-BASED BIOMARKERS AND RADIOMICS

Status: Enrolling

Investigator: Nestor Esnaola

Study Coordinator: Derek Cole

Phone: 713.441.5607

This is a prospective study that will recruit male and female study participants, ages 55 to 80, already enrolled in Lung Cancer Screening program at all Houston Methodist Hospital locations. The goal of this study is to develop powerful inte ... Read more >